The role of indium-III radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients

Clinical Medicine and Research

Volumn 5, Issue 2, 2007, Pages 123-131

  Jani, Ashesh B ^a   Liauw, Stanley L ^b   Blend, Michael J ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Prostate cancer; Radioimmunoscintigraphy; Radiotherapy

Indexed keywords

CAPROMAB PENDETIDE IN 111; INDIUM 111; PROSTATE SPECIFIC MEMBRANE ANTIGEN; DIAGNOSTIC AGENT; INDIUM;

ANTIBODY LABELING; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECISION MAKING; HEALTH CARE PLANNING; HUMAN; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RADIOIMMUNOSCINTIGRAPHY; RECTUM DISEASE; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RADIATION DOSE; RADIOIMMUNOASSAY; REVIEW; SCINTISCANNING;

COMBINED MODALITY THERAPY; HUMANS; INDIUM RADIOISOTOPES; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOIMMUNODETECTION; SENSITIVITY AND SPECIFICITY;

EID: 38949212270     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2007.740     Document Type: Article

References (64)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864.
2. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003;361:1045-1053.
3. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315.
4. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 2000;48:369-375.
5. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigni RG. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996;156:1725-1729.
6. Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:600-609.
7. Kalapurakal JA, Huang CF, Neriamparampil MM, Small WJ Jr, Pins MR, Mittal BB, Campbell SC, Grayhack JT, Shetty RM. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002;54:1047-1054.
8. Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Spry N, Turner S, Woo H. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology 2003;61:179-183.
9. Do T, Parker RG, Do C, Tran L, Do L, Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 1998;4:324-330.
10. Jacobson GM, Smith JA Jr, Stewart JR. Postoperative radiation therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 1987;13:1021-1024.
11. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-2335.
12. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-578.
13. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-1332.
14. Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis. Cancer 2005;103:1833-1842.
15. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001;219:432-439.
16. Miralbell R, Vees H, Lozano J, Khan H, Molla M, Hidalgo A, Linero D, Rouzaud M. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 2007;67:356-361.
17. Hocht S, Wiegel T, Bottke D, Jentsch H, Sternemann M, Rosenthal P, Hinkelbein W. Computed tomogram prior to prostatectomy. Advantage in defining planning target volumes for postoperative adjuvant radiotherapy in patients with stage C prostate cancer? Strahlenther Onkol 2002;178:134-1348.
18. Pilepich MV, Prasad SC, Perez CA. Computed tomography in definitive radiotherapy of prostatic carcinoma, part 2: definition of target volume. Int J Radiat Oncol Biol Phys 1982;8:235-239.
19. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003;61:607-611.
20. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006;3:216-225.
21. Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, Burgers JK, Texter JH, Neal CE, Libertino JA, Wright GL Jr, Maguire RT. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999;54:1058-1063.
22. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000;25:33-40.
23. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, Maguire R, Rogers B, Olsen JO, Badalament RA. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-747.
24. Murphy GP, Elgamal AA, Troychak MJ, Kenny GM. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 2000;42:315-317.
25. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000;56:988-993.
26. Blend MJ and Sodee DB. ProstaScint: an update. In: Freeman LM, ed. Nuclear medicine annual. Philadelphia, PA: Lipincott Williams and Wilkins; 2001. 109-142.
27. Feneley MR, Jan H, Granowska M, Mather SJ, Ellison D, Glass J, Coptcoat M, Kirby RS, Ogden C, Oliver RT, Badenoch DF, Chinegwundoh FI, Nargund VH, Paris AM, Britton KE. Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 2000;3:47-52.
28. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94:987-996.
29. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998;16:284-289.
30. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, McLaughlin PW, DeBiose DA, Hussey DH, Wahl RL. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003;21:1715-1721.
31. Nagda SN, Mohideen N, Lo SS, Khan U, Dillehay G, Wagner R, Campbell S, Flanigan R. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2007;67:834-840.
32. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
33. Ellis RJ, Kaminsky DA. Fused radioimmunoscintigraphy for treatment planning. Rev Urol 2006;8:S11-S19.
34. Ellis RJ, Kim EY, Conant R, Sodee DB, Spirnak JP, Dinchman KH, Beddar S, Wessels B, Resnick MI, Kinsella TJ. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001;49:1281-1286.
35. Ellis RJ, Kim E, Foor R. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma. Expert Rev Mol Diagn 2004;4:435-441.
36. Ellis RJ, Vertocnik A, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2003;57:362-370.
37. Jani AB, Blend MJ, Hamilton R, Brendler C, Pelizzari C, Krauz L, Vijayakumar S, Sapra B, Awan A, Weichselbaum RR. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med 2004;45:571-578.
38. Teh BS, Mai WY, Augspurger ME, Uhl BM, McGary J, Dong L, Grant WH 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 2001;49:465-472.
39. Jani AB, Roeske JC, Rash C. Intensity-modulated radiation therapy for prostate cancer. Clin Prostate Cancer 2003;2:98-105.
40. Jani AB, Spelbring D, Hamilton R, Blend MJ, Pelizzari C, Brendler C, Krauz L, Vijayakumar S, Sapra B, Weichselbaum RR. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med 2004;45:238-246.
41. Hamilton RJ, Blend MJ, Pelizzari CA, Milliken BD, Vijayakumar S. Using vascular structure for CT-SPECT registration in the pelvis. J Nucl Med 1999;40:347-351.
42. Hamilton RJ, Blend MJ, Blend D. Use of ProstaScint CT image registration in the post-operative radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2000;38:358-359.
43. Su A, Blend MJ, Spelbring D, Hamilton RJ, Jani AB. Postprostatectomy target-normal structure overlap volume differences using computed tomography and radioimmunoscintigraphy images for radiotherapy treatment planning. Clin Nucl Med 2006;31:139-144.
44. Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libertino JA. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51:978-984.
45. Proano JM, Sodee DB, Resnick MI, Einstein DB. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol 2006;175:1668-1672.
46. Liauw SL, Jani AB, Zagaja G, Weichselbaum RR. Salvage RT after post-prostatectomy biochemical failure: outcomes for patients with no extraprostatic disease on radioimmunoscintigraphy. Proceedings of American Radium Society, 2007 (in press).
47. Wilkinson S, Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 2004;172:133-136.
48. Jani AB, Blend MJ, Hamilton R, Brendler C, Pelizzari C, Krauz L, Sapra B, Vijayakumar S, Awan A, Weichselbaum RR. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med 2004;45:1315-1322.
49. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155.
50. Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 2001;40:481-487.
51. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-555.
52. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S, Canini R, Grigioni WF, D'Errico Grigioni A. 11C-choline positron emission tomography/ computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-960.
53. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
54. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236:545-553.
55. Noz ME, Chung G, Lee BY, Maguire GQ Jr, DeWyngaert JK, Doshi JV, Kramer EL, Murphy-Walcott AD, Zeleznik MP, Kwak NG. Enhancing the utility of prostascint SPECT scans for patient management. J Med Syst 2006;30:123-132.
56. Sychra JJ, Lin KQ, Blend MJ. Detection of metastatic prostate cancer with simultaneous dual radioisotope SPECT images. RSNA Electronic Journal 1997;1. Available at: http://ej.rsna.org/EJ_0_96/0034-97.fin/ prostate.htm. Accessed April 17, 2007.
57. DeWyngaert JK, Noz ME, Ellerin B, Kramer EL, Maguire GQ Jr, Zeleznik MP. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 2004;60:654-662.
58. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer 2005;3:230-238.
59. Seo Y, Franc BL, Hawkins RA, Wong KH, Hasegawa BH. Progress in SPECT/CT imaging of prostate cancer. Technol Cancer Res Treat 2006;5:329-336.
60. Sodee D, Novak R, Sodee A, Ellis R. Retrospective diagnostic analysis of localized prostate cancer comparing needle core biopsy results to ProstaScint/SPECT fused with CT. J Nucl Med 2006;47:457P.
61. Sasaki A, Gordon L. Improved disease detection with fusion of ProstaScint scans and multidetector CT. J Nucl Med 2006;47:245P.
62. Ziffer J, Janowitz W, Vuong H, Elgarresta L, Acosta J, Hernandez R, Bellmas L. Hybrid imaging with single photon emission and x-ray computed tomography: Initial experience with 332 patients using an integrated 16-slice high-speed CT with a dual head SPECT device. J Nucl Med 2006;47:266P.
63. Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol 2004;11:2110-2117.
64. Jani AB. Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique. Cancer Invest 2006;24:318-327.